Objectives and Study:
The CoMiSS score was developed as an easy-to-use awareness tool for primary health care providers to increase the awareness of the most common symptoms of cow's milk protein allergy (CMPA) and the evolution of symptoms during a therapeutic intervention. The purpose of the study was to evaluate the score in infants with symptoms indicative of CMPA and to evaluate its usefulness in the clinical practice.
Methods:
The study took place in 4 European countries (Belgium (BE), Czech Republic (CZ), Germany (GER), United-Kingdom (UK)) and the dietary intervention was according to the current practice of the participating HCP in order to obtain “real world data”. CoMiSS was determined in 268 infants and young children (145 boys, 117 girls) aged 0-18 months at the first visit upon presenting symptoms suggesting CMPA and again after 3 weeks of a dietary intervention, with a cow milk protein free diet.
Results:
The characteristics, of the infants included, differed according to the country at first visit for age in weeks [mean ± SD] (12.7 ± 10.0 for BE; 24.1 ±14.2 for CZ; 21.4 ± 17.7 for GER; 34.1 ± 17.7 for UK) and duration of symptoms in weeks [mean ±SD] (6.9 ± 9.1 for BE, 11.5 ±10.4 for CZ, 9.7 ± 12.4 for GER and 24.0 ± 15.4 for UK ) In all countries, weight and height were in line with the reference growth chart and no growth failure was recorded before diagnosis. The median (IQR) CoMiSS score at inclusion was 11 (8-14) overall, 11 (8-14) in BE, 13 (12-16) in CZ, 8 (6-10) in GER and 7 (4-10) in UK. After 3 weeks of intervention per routine prescription the median (IQR) CoMiSS scores was 4 (2-6) and per country: BE 4 (2-6), CZ 3 (2-5), GER 4 (2-6), UK 3 (1-6). The scores after 3 weeks are in line with those considered as normal in healthy infants. At the first visit, 145/268 were prescribed medication for their symptoms with 35 (13%) taking one or more antacids. Additional medication was prescribed in 48 (18%), including 8 given a new prescription for an antacid. Data were analyzed per Intention to Treat and Per Protocol without notable differences.
Conclusions:
This study confirms that CoMiSS is a useful tool to increase the awareness of CMPA "in real life". Differences were noted between the four countries.
Reference
The cow's milk-related symptoms score (CoMiSS™): a useful tool in the clinical setting - results from an observational study. Yvan Vandenplas, Elisabeth Belsey, Anette Jarvi, Philippe Steenhout. Abstract presented at the annual ESPGHAN congress, June 6. JPGN Volume 68, Supplement 1, May 2019.
IMPORTANT NOTICE: Mothers should be encouraged to continue breastfeeding even when their infants have cows’ milk protein allergy. This usually requires qualified dietary counselling to completely exclude all sources of cows’ milk protein from the mothers’ diet. If a decision to use a special formula intended for infants is taken, it is important to give instructions on correct preparation methods, emphasising that unboiled water, unsterilised bottles or incorrect dilution can all lead to illness. Formula for special medical purposes intended for infants must be used under medical supervision.
The CoMiSS score was developed as an easy-to-use awareness tool for primary health care providers to increase the awareness of the most common symptoms of cow's milk protein allergy (CMPA) and the evolution of symptoms during a therapeutic intervention. The purpose of the study was to evaluate the score in infants with symptoms indicative of CMPA and to evaluate...